SCHEDULE: Janus Henderson Boosts Ascendis Pharma Stake to 8.0%

Janus Henderson Group plc has increased its beneficial ownership in Ascendis Pharma A/S to 8.0% of American Depositary Shares, holding 4,427,792 shares.

Summary

• Janus Henderson Group plc reported beneficial ownership of 4,427,792 American Depositary Shares (ADS) of Ascendis Pharma A/S.
• This represents 8.0% of the class of securities.
• The shares are held with shared voting power and shared dispositive power.
• The event date requiring this filing is stated as June 30, 2025.
• The acquisition of these securities was made in the ordinary course of business and not for the purpose of changing or influencing the control of Ascendis Pharma A/S.

Sentiment

Score: 7

Explanation: The filing indicates a significant and continued passive investment by a major institutional investor, Janus Henderson Group plc, in Ascendis Pharma A/S. Maintaining an 8.0% stake suggests ongoing confidence in the company's long-term prospects, which is generally viewed positively by the market.

Positives

• Janus Henderson Group plc, a major institutional investment firm, maintains a significant 8.0% stake in Ascendis Pharma A/S, indicating continued confidence in the company's long-term prospects.

Negatives

• No explicit negative information is typically disclosed in a Schedule 13G filing, which primarily reports beneficial ownership.

Risks

• The securities are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of Ascendis Pharma A/S.

Future Outlook

This filing does not provide forward-looking statements or guidance from Ascendis Pharma A/S, as it is a beneficial ownership report by an investor.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11." (Kristin Mariani, Head of North America Compliance, CCO for Janus Henderson Group plc)

Industry Context

This filing reflects a significant passive investment by a major asset manager, Janus Henderson Group plc, in Ascendis Pharma A/S, a biotechnology company. Such substantial institutional holdings are common in the pharmaceutical sector, where long-term investment in drug development companies is typical.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holding, potentially signaling investor confidence.
• Management: Awareness of a large passive shareholder, but no direct impact on control or operations.

Next Steps

• No specific future actions or milestones for Ascendis Pharma A/S are detailed in this beneficial ownership report.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant passive ownership stake by Janus Henderson Group plc in Ascendis Pharma A/S. While the continued substantial holding (8.0%) by a major institutional investor can be seen as a positive signal of confidence, the filing itself does not contain sufficient financial or operational details to warrant a 'buy' or 'sell' recommendation. It confirms a stable, non-controlling institutional presence, suggesting a 'hold' position for existing investors who may view this as a reaffirmation of long-term interest.

Keywords

Ascendis Pharma, Janus Henderson, Schedule 13G, Beneficial Ownership, American Depositary Shares, Biotechnology, Pharmaceuticals, Investment